Heptares
AstraZeneca trigger $10 million milestone payment for Heptares in immuno-oncology candidate
July 6, 2016Research and Development, Sales and Marketing AstraZeneca, Heptares
AstraZeneca (LSE: AZN) is set to deliver a payment of $10 million to Heptares Therapeutics after the first patient was …
Allergan to partner with Heptares in Alzheimer’s disease collaboration
April 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Alzheimer's, Heptares, R&D, collaboration, commercialisation, h1, h4, neurological disorders, partnership, research and development, treatments
Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan (NYSE:AGN) has announced a new …
Heptares announces positive early-stage dementia trial results
February 10, 2016Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia
Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …
Teva and Heptares enter $400m agreement for small-molecule migraine treatment
November 25, 2015Research and Development Heptares, Teva, collaboration, migraine
Teva Pharmaceuticals and Heptares Therapeutics have signed a licensing and drug-discovery agreement for Teva to gain exclusive global rights to …
Heptares awarded $5.5 million grant to combat cocaine addiction
September 30, 2015Research and Development Heptares
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, has been awarded a grant from the National Institute …
Valeant to buy Salix in $14.5 billion move
February 23, 2015Sales and Marketing Deals, Heptares, Valeant, mergers, salix, sosei
Valeant has agreed a deal to acquire US-based speciality manufacturer of gastrointestinal drugs Salix in a move worth around $14.5 …
Heptares Therapeutics hires former GSK heads
January 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Atul Pande, GSK, Heptares, Roberto Solari
UK and US-based clinical-stage drug firm Heptares Therapeutics has appointed Atul Pande and Roberto Solari to its board of directors. …
Heptares appoints Tim Tasker as chief medical officer


January 16, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Heptares, tim tasker
Drug development firm Heptares Therapeutics has appointed Dr Tim Tasker as its chief medical officer (CMO) and VP of Development. …
Amgen’s Roger Perlmutter joins Heptares
October 23, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Heptares, Roger Perlmutter
GPCR drug discovery firm Heptares Therapeutics has elected Dr Roger Perlmutter, the former executive VP, Research and Development, at Amgen …
Shire signs CNS disorders deal with Heptares
March 23, 2012Research and Development A2A, CNS, GPCR, Heptares, Shire
Shire is to develop and commercialise a novel adenosine A2A antagonist discovered by Heptares currently in pre-clinical development.UK-based Heptares discovers and …
Daniel Grau appointed as president of Heptares
November 8, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Daniel Grau, Heptares
Daniel Grau has been appointed as president of Heptares Therapeutics, a specialist in G-protein-coupled receptors. Mr Grau has been a …
